United States should end gene therapy review panel, study says
December 9, 2013
After 4 decades of vetting clinical trials of gene therapy for novel risks, it’s time to relax a bit, says a report issued today by an expert panel. But key government officials are greeting the recommendation with caution. Gene therapy has proved its value, and its leaders have managed ethics issues well, according to a panel convened by the Institute of Medicine (IOM) at the U.S. National Academies. The long-term hazards of gene therapy may not be clear yet, but the general risks seem no greater than in other areas of experimental medicine, the report says, so it’s time to phase out the U.S. outfit created in 1974 that’s dedicated to reviewing gene therapy, the Recombinant DNA Advisory Committee, or RAC. (Science)